Reduced Toxicity Conditioning Prior to Unrelated Cord Cell Transplantation for High Risk Myeloid Malignancies

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

31 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-05-31

Study Completion Date

2019-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Allogeneic cord blood stem cell transplantation is a potentially curative therapy for patients with haematological malignancies. We have extensive experience with the use of Cord Blood Transplantation (CBT) in patients with advanced myeloid malignancies. In adults however, the 40% Non-Relapse Mortality (NRM) rate observed after CBT conditioned with a myeloablative conditioning has encouraged the development of CBT with Reduced Intensity Conditioning (RIC). Our previous national CBT protocol (the Minicord French protocol - NCT00797758) showed that RIC CBT can reduce NRM, but relapse remains the main post-transplant event (\>30% at one year). Thus, the development of reduced toxicity rather than RIC conditioning for CBT is warranted in order to improve the outcome of such transplants by limiting NRM and reducing relapse rate. The Fludarabine, ATG and intensified doses of IV Busulfan (9.6 mg/Kg total dose) regimen is a well-established preparative regimen for reduced-intensity/toxicity conditioning prior to allogeneic stem cell transplantation using peripheral blood stem cells mobilized with G-CSF (ClinicalTrials.gov Identifier: NCT00841724). However, such regimen is likely not sufficient to allow for CB cell engraftment. Thiotepa is an alkylating and radio-mimetic agent with a large anti-tumor activity including leukemic cells, the ability to cross the blood-brain barrier and to improve engraftment of hematopoietic stem cells. This drug has been combined to usual conditioning regimen without increasing the toxicity but improving the engraftment rate and potentially reducing the relapse rate. Thus, in the context of adult CBT for high risk myeloid malignancies, we propose to prospectively evaluate a reduced toxicity conditioning based on the association of Thiotepa, Fludarabine, IV Busulfan and ATG with the objective to achieve acceptable NRM rates, and to allow for improved anti-leukemic control based on the cytotoxic component of the conditioning regimen itself, while waiting for the long term immune-mediated disease control (GVL effect).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Reduced Toxicity Myeloablative Conditioning Regimen for Cord Blood Transplantation in Pediatric AML

NCT00887042

Acute Myeloid Leukemia

UNKNOWN PHASE1/PHASE2

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

NCT06013423

Acute Leukemia of Ambiguous Lineage Acute Lymphoblastic Leukemia Acute Myeloid Leukemia +7 more

RECRUITING PHASE2

Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies

NCT00270881

Acute Myelogenous Leukemia Acute Lymphoblastic Leukemia Chronic Myelogenous Leukemia +1 more

COMPLETED PHASE1/PHASE2

Pilot Study of Unrelated Cord Blood Transplantation

NCT00916045

Leukemia, Myeloid, Acute Myelodysplastic Syndromes Leukemia, Lymphoblastic, Acute +3 more

TERMINATED PHASE2

Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501)

NCT00412360

Acute Myelogenous Leukemia Acute Lymphocytic Leukemia Chronic Myelogenous Leukemia +2 more

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Leukemia, Myeloid

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Reduced toxicity conditioning regimen

Reduced toxicity conditioning regimen (thiotepa, busulfan, fludarabine and ATG) followed by unrelated cord blood allogeneic stem cell transplant for high risk myeloïd malignancies.

The conditioning regimen will include:

* IV Thiotepa (5 mg/Kg/day for 2 days) (Day -7 and -6)
* IV fludarabine (40 mg/m²/day for 4 days) (from Day-5 to day -2)
* IV Busulfan (Busilvex 130 mg/m2/day for 3 days) (Day-5, -4 and -3)
* IV Anti-thymocyte globuline (Thymogobuline®, 2.5 mg/kg/day for 2 days) (Day-3 and -2)

In patient with co-morbidities and/or older than 60 years, conditioning could be reduced after consulting the coordinator of the study:

* IV Thiotepa (5 mg/Kg/day for 2 days) (Day -6)
* IV fludarabine (40 mg/m²/day for 4 days) (from Day-5 to day -2)
* IV Busulfan (Busilvex 100 mg/m2/day for 3 days) (Day-5, -4 and -3)
* IV Anti-thymocyte globuline (Thymogobuline®, 2.5 mg/kg/day for 2 days) (Day-3 and -2)

Group Type EXPERIMENTAL

IV Thiotepa

Intervention Type DRUG

IV Thiotepa (5 mg/Kg/day for 2 days) (Day -7 and -6) or IV Thiotepa (5 mg/Kg/day for 2 days) (Day -6)

IV Fludarabine

Intervention Type DRUG

IV fludarabine (40 mg/m²/day for 4 days) (from Day-5 to day -2)

IV Busulfan

Intervention Type DRUG

(Busilvex 130 mg/m2/day for 3 days) (Day-5, -4 and -3) or (Busilvex 100 mg/m2/day for 3 days) (Day-5, -4 and -3)

IV Anti-thymocyte globuline

Intervention Type DRUG

(Thymogobuline®, 2.5 mg/kg/day for 2 days) (Day-3 and -2)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IV Thiotepa

IV Thiotepa (5 mg/Kg/day for 2 days) (Day -7 and -6) or IV Thiotepa (5 mg/Kg/day for 2 days) (Day -6)

Intervention Type DRUG

IV Fludarabine

IV fludarabine (40 mg/m²/day for 4 days) (from Day-5 to day -2)

Intervention Type DRUG

IV Busulfan

(Busilvex 130 mg/m2/day for 3 days) (Day-5, -4 and -3) or (Busilvex 100 mg/m2/day for 3 days) (Day-5, -4 and -3)

Intervention Type DRUG

IV Anti-thymocyte globuline

(Thymogobuline®, 2.5 mg/kg/day for 2 days) (Day-3 and -2)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Thiotepa Fludarabine Busulfan Anti-thymocyte globuline

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥18 years and ≤ 65 years
* Patients diagnosed with one of the following diseases (validation of the indication of allogeneic

HSCT with an alternative source of hematopoietic stem cells by centers' local RCP):

* Acute myelogenous leukemia (AML) with intermediate or high risk features ((≥ intermediate risk 1) in CR1 or above according to centers' decision
* Myelodysplastic syndromes with International Prognostic Scoring System (IPSS) score ³ 2 (cf. appendix 3) or with symptomatic pancytopenia according to centers' decision
* Chronic myelomonocytic leukemia (CMML)
* Both MDS and CMML should have ≤ 10% blasts at transplantation
* Absence of a matched sibling or unrelated donor (10/10 or 9/10 if mismatch on HLA Cw, based on each center's donor selection criteria)
* Cord blood units must be matched with patient at 4, 5, or 6/6 HLA loci, (class I antigenic \& class II allelic level)with a minimum of 3.5 x 10\^7 TNC/kg recipient body weight in the pre-thawed fraction and with ≥2.5x10\^7 TNC/kg for the richest cord blood unit and ≥ 1.5x10\^7 TNC/kg for the poorest blood unit in case of 2 cord blood units
* Performance status : OMS score ≤ 1 (cf. appendix 5)
* Cardiac function - left ventricular ejection fraction ≥ 45%.
* Pulmonary function - diffusion capacity of at least 50% predicted.
* Serum creatinine clearance 0 ml/min.
* SGPT 4x normal , serum bilirubin \< 2 x normal.
* Written informed consent.
* Progestative treatment for women with persisting menstrual periods

Exclusion Criteria

* Presence of a matched sibling or unrelated available donor (10/10 or 9/10 if mismatch on HLA Cw in centers performing 9/10 HLA mismatched transplants)
* Active infection at time of conditioning. In case of uncertainty regarding whether a previous infection is resolved or not, this will be discussed with the PI on a case by case basis.
* Pregnancy in women with child bearing potential (pregnancy test performed within 2-4 weeks of study entry).
* HIV positive
* Active CNS leukemia
* Chronic or active Hepatitis B or Hepatitis C. If questions about liver health discuss with PI and strongly consider liver biopsy.
* Poor performance status : OMS score \> 1
* Life expectancy is severely limited by concomitant illness and expected to be \<12 weeks.
* Left ventricular ejection fraction \<45%. Uncontrolled arrhythmias or symptomatic cardiac disease.
* Symptomatic pulmonary disease. FEV1, FVC and DLCO \<50% of expected corrected for hemoglobin.
* Serum creatinine clearance (Crockoft) below 50 mL/m per 1.73 m² or requiring dialysis
* Vaccination with alive vaccine (virus or bacteria) \< 3 months
* Fludarabine contra-indication
* Thymoglobuline contra-indication
* Patient under guardianship or curatorship

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No